These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 28131405)

  • 21. Diabetes and cardiovascular disease: it's time to apply the evidence.
    Grant PJ; Marx N
    Eur Heart J Acute Cardiovasc Care; 2020 Sep; 9(6):586-588. PubMed ID: 33203234
    [No Abstract]   [Full Text] [Related]  

  • 22. The prevalence and management of diabetes in rural India.
    Chow CK; Raju PK; Raju R; Reddy KS; Cardona M; Celermajer DS; Neal BC
    Diabetes Care; 2006 Jul; 29(7):1717-8. PubMed ID: 16801618
    [No Abstract]   [Full Text] [Related]  

  • 23. Paradigm shift in the management of DM & CVD-preventing the next CV event.
    Handelsman Y; Bloomgarden Z
    J Diabetes; 2020 Sep; 12(9):630-632. PubMed ID: 32573096
    [No Abstract]   [Full Text] [Related]  

  • 24. Prevalence of treatment for diabetes during 1997-2007, and trends in cardiovascular risk factors between 2001 and 2007 according to diabetic treatment, in the IPC (Investigations Préventives et Cliniques; Preventive and Clinical Investigations) cohort.
    Thomas F; Eschwege E; Bean K; Pannier B; Danchin N
    Diabetes Metab; 2013 Sep; 39(4):343-8. PubMed ID: 23642643
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug safety. Planned study of Avandia in doubt after FDA review.
    Kean S
    Science; 2010 Jul; 329(5990):375. PubMed ID: 20651123
    [No Abstract]   [Full Text] [Related]  

  • 26. Watch out for diabetes: Less education but let's get moving, let's eat less!
    Argano C; Bocchio RM; Corrao S
    Eur J Intern Med; 2016 Jul; 32():e15-6. PubMed ID: 27179415
    [No Abstract]   [Full Text] [Related]  

  • 27. Implications of new diabetes treatment trials: should current clinical practice be altered?
    Kravetz JD; Federman DG
    Postgrad Med; 2009 May; 121(3):67-72. PubMed ID: 19491542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of 16-week monotherapy with acarbose on cardiovascular risk factors in obese subjects with non-insulin-dependent diabetes mellitus: a controlled, double-blind comparison study with placebo.
    Calle-Pascual A; Garcia-Honduvilla J; Martin-Alvarez PJ; Calle JR; Maranes JP
    Diabetes Metab; 1996 Jun; 22(3):201-2. PubMed ID: 8697309
    [No Abstract]   [Full Text] [Related]  

  • 29. [ESC guidelines on diabetes, pre-diabetes and diseases of the cardiovascular system developed in cooperation with the EASD].
    ; Rydén L; Grant PJ; Anker SD; Berne C; Cosentino F; Danchin N; Deaton C; Escaned J; Hammes HP; Huikuri H; Marre M; Marx N; Mellbin L; Ostergren J; Patrono C; Seferovic P; Sousa Uva M; Taskinen MR; Tendera M; Tuomilehto J; Valensi P; Zamorano JL;
    Kardiol Pol; 2013; 71 Suppl 11():S319-94. PubMed ID: 24297732
    [No Abstract]   [Full Text] [Related]  

  • 30. The association between co-morbidity and the use of antidiabetics or adjunctive cardiovascular medicines in Australian veterans with diabetes.
    Zhang Y; Vitry A; Caughey G; Roughead EE; Ryan P; Gilbert A; Shakib S; McDermott R
    Diabetes Res Clin Pract; 2011 Jan; 91(1):115-20. PubMed ID: 21067836
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regarding "Pharmacologic risk factor management in peripheral arterial disease: a vade mecum for vascular surgeons".
    Paraskevas KI
    J Vasc Surg; 2008 Sep; 48(3):776-7; author reply 777. PubMed ID: 18727983
    [No Abstract]   [Full Text] [Related]  

  • 32. Developing new drugs for diabetes and cardiometabolic disorders: a changing paradigm.
    Krentz AJ; Morrow L; Hompesch M
    Drugs; 2012 Sep; 72(13):1709-11. PubMed ID: 22931519
    [No Abstract]   [Full Text] [Related]  

  • 33. The global implications of diabetes and cancer.
    Shi Y; Hu FB
    Lancet; 2014 Jun; 383(9933):1947-8. PubMed ID: 24910221
    [No Abstract]   [Full Text] [Related]  

  • 34. Does intensive glycemic control improve cardiovascular outcomes?
    Pendergrass M
    Nat Clin Pract Endocrinol Metab; 2008 Oct; 4(10):529. PubMed ID: 18806805
    [No Abstract]   [Full Text] [Related]  

  • 35. Glycemic control and cardiovascular mortality.
    Riddle MC
    Curr Opin Endocrinol Diabetes Obes; 2011 Apr; 18(2):104-9. PubMed ID: 21522000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. How important is diabetes as a risk factor for cardiovascular and other diseases in older adults?
    Kengne AP; Patel A
    PLoS Med; 2006 Oct; 3(10):e424. PubMed ID: 17048981
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Foreword.
    Curr Probl Cardiol; 2018 Mar; 43(3):65. PubMed ID: 29471917
    [No Abstract]   [Full Text] [Related]  

  • 38. Cardiovascular safety of anti-diabetic drugs.
    Kumar R; Kerins DM; Walther T
    Eur Heart J Cardiovasc Pharmacother; 2016 Jan; 2(1):32-43. PubMed ID: 27533060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Anti-diabetic therapy and cardiovascular disease].
    Mannucci E
    G Ital Cardiol (Rome); 2016 Mar; 17(3 Suppl 2):3s-4. PubMed ID: 27030117
    [No Abstract]   [Full Text] [Related]  

  • 40. Prevalence of newly diagnosed diabetes in clinical settings.
    Nesto RW
    Rev Cardiovasc Med; 2006; 7 Suppl 2():S18-24. PubMed ID: 17224873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.